Catalyst Event
Sanofi (SNY) · Other
From KEDI U.S. Tech100 90% Participation + Daily Options Premium Index (KUSTC100P)
5/28/2026, 12:00:00 AM
The U.S. FDA granted Priority Review to the New Drug Application for venglustat for the treatment of type 3 Gaucher disease (GD3), a rare disorder. The target action date is November 25, 2026.
Korean Translation
미국 FDA, 희귀질환인 제3형 고셔병 치료제 벤글루스탯의 신약 허가 신청(NDA)에 대해 우선 심사 자격 부여함. FDA 결정 목표일은 2026년 11월 25일임.
Related Recent Events
Cisco Systems Inc (CSCO) · Earnings Release
Cisco's Q4 and full fiscal year 2026 earnings release scheduled for August 12, 2026, is assigned high importance due to an estimated price impact of over 10%, scheduled.
8/12/2026, 12:00:00 AM
Gilead Sciences Inc (GILD) · Earnings Release
Gilead's Q2 2026 earnings release is scheduled.
8/6/2026, 12:00:00 AM
Rocket Lab Corp (RKLB) · Earnings Release
The Q2 2026 earnings release for Rocket Lab is set for August 6, 2026, scheduled.
8/6/2026, 12:00:00 AM
Advanced Micro Devices Inc (AMD) · Earnings Release
Q2 2026 earnings release scheduled for August 4, 2026. Analysts project an EPS of $1.55 estimated. Medium importance reflects typical volatility around earnings releases.
8/4/2026, 12:00:00 AM
Monolithic Power Systems Inc (MPWR) · Earnings Release
Monolithic Power Systems Q2 2026 earnings release on 2026-07-30 with analysts forecast of $5.85 EPS forecasted. High importance expected due to historical price volatility during earnings expected.
7/30/2026, 12:00:00 AM
QUALCOMM Inc. (QCOM) · Earnings Release
Qualcomm is expected to release its fiscal Q3 2026 earnings results on July 29, 2026, expected.
7/29/2026, 12:00:00 AM